Topic
Pegvisomant
About: Pegvisomant is a research topic. Over the lifetime, 545 publications have been published within this topic receiving 18341 citations. The topic is also known as: GH-N & Growth hormone.
Papers published on a yearly basis
Papers
TL;DR: The most important cause of morbidity and functional disability of this disease is arthropathy, which can be reversed at an initial stage, but not if the disease is left untreated for several years.
Abstract: This review focuses on the systemic complications of acromegaly. Mortality in this disease is increased mostly because of cardiovascular and respiratory diseases, although currently neoplastic complications have been questioned as a relevant cause of increased risk of death. Biventricular hypertrophy, occurring independently of hypertension and metabolic complications, is the most frequent cardiac complication. Diastolic and systolic dysfunction develops along with disease duration; and other cardiac disorders, such as arrhythmias, valve disease, hypertension, atherosclerosis, and endothelial dysfunction, are also common in acromegaly. Control of acromegaly by surgery or pharmacotherapy, especially somatostatin analogs, improves cardiovascular morbidity. Respiratory disorders, sleep apnea, and ventilatory dysfunction are also important contributors in increasing mortality and are advantageously benefitted by controlling GH and IGF-I hypersecretion. An increased risk of colonic polyps, which more frequently recur in patients not controlled after treatment, has been reported by several independent investigations, although malignancies in other organs have also been described, but less convincingly than at the gastrointestinal level. Finally, the most important cause of morbidity and functional disability of the disease is arthropathy, which can be reversed at an initial stage, but not if the disease is left untreated for several years.
1,318 citations
1,025 citations
TL;DR: Treatment of patients who have acromegaly with pegvisomant with a growth hormone–receptor antagonist results in a reduction in serum IGF-I concentrations and in clinical improvement.
Abstract: Background Patients with acromegaly are treated with surgery, radiation therapy, and drugs to reduce hypersecretion of growth hormone, but the treatments may be ineffective and have adverse effects. Pegvisomant is a genetically engineered growth hormone–receptor antagonist that blocks the action of growth hormone. Methods We conducted a 12-week, randomized, double-blind study of three different daily doses of pegvisomant (10 mg, 15 mg, and 20 mg) and placebo, given subcutaneously, in 112 patients with acromegaly. Results The mean (±SD) serum concentration of insulin-like growth factor I (IGF-I) decreased from base line by 4.0±16.8 percent in the placebo group, 26.7± 27.9 percent in the group that received 10 mg of pegvisomant per day, 50.1±26.7 percent in the group that received 15 mg of pegvisomant per day, and 62.5±21.3 percent in the group that received 20 mg of pegvisomant per day (P<0.001 for the comparison of each pegvisomant group with placebo), and the concentrations became normal in 10 percent, 54 percent, 81 percent, and 89 percent of patients, respectively (P<0.001 for each comparison with placebo). Among patients treated with 15 mg or 20 mg of pegvisomant per day, there were significant decreases in ring size, soft-tissue swelling, the degree of excessive perspiration, and fatigue. The score for total symptoms and signs of acromegaly decreased significantly in all groups receiving pegvisomant (P«0.05). The incidence of adverse effects was similar in all groups. Conclusions On the basis of these preliminary results, treatment of patients who have acromegaly with a growth hormone–receptor antagonist results in a reduction in serum IGF-I concentrations and in clinical improvement. (N Engl J Med 2000;342:1171-7.)
836 citations
Cedars-Sinai Medical Center1, University of Naples Federico II2, University of Michigan3, Northwestern University4, St Bartholomew's Hospital5, New York University6, University of North Carolina at Chapel Hill7, University of Paris-Sud8, Harvard University9, University of Iowa10, University of Virginia11, Garvan Institute of Medical Research12, University of Brescia13
TL;DR: The group developed a consensus on the approach to managing acromegaly including appropriate roles for neurosurgery, medical therapy, and radiation therapy in the management of these patients.
Abstract: Objective: The Acromegaly Consensus Group reconvened in November 2007 to update guidelines for acromegaly management. Participants: The meeting participants comprised 68 pituitary specialists, including neurosurgeons and endocrinologists with extensive experience treating patients with acromegaly. Evidence/Consensus Process: Goals of treatment and the appropriate imaging and biochemical and clinical monitoring of patients with acromegaly were enunciated, based on the available published evidence. Conclusions: The group developed a consensus on the approach to managing acromegaly including appropriate roles for neurosurgery, medical therapy, and radiation therapy in the management of these patients.
790 citations
Erasmus University Rotterdam1, University of Tennessee2, St Bartholomew's Hospital3, University of Michigan4, Harvard University5, Cedars-Sinai Medical Center6, University of Virginia7, Columbia University8, Queen Elizabeth Hospital Birmingham9, University of Texas MD Anderson Cancer Center10, University of North Carolina at Chapel Hill11, Sahlgrenska University Hospital12, New York University13, Oregon Health & Science University14, Emory University15, Ludwig Maximilian University of Munich16
TL;DR: Pegvisomant is an effective medical treatment for acromegaly and of the patients treated for 12 months or more, 87 of 90 (97%) achieved a normal serum IGF-1 concentration.
660 citations
Related Topics (5)
Performance Metrics
| Year | Papers |
|---|---|
| 2025 | 3 |
| 2024 | 8 |
| 2023 | 14 |
| 2022 | 40 |
| 2021 | 19 |
| 2020 | 32 |